Despite these limitations, our in vitro assays, albeit constrained by a smaller sample size, demonstrated the beneficial effects of VitD in reducing p24 concentration, AKT phosphorylation, and glucose uptake, suggesting that VitD’s capacity to decrease cellular activation may result in reduced HIV infection. The gene discussed is AKT1; the disease is HIV infectious disease.